Bio-Rad Laboratories, Inc. (BIO) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BIO Revenue Growth
Revenue Breakdown (FY 2025)
BIO's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
BIO Revenue Analysis (2014–2025)
As of May 6, 2026, Bio-Rad Laboratories, Inc. (BIO) generated trailing twelve-month (TTM) revenue of $2.59 billion, reflecting modest growth of +1.1% year-over-year. The most recent quarter (Q1 2026) recorded $592.1 million in revenue, down 14.6% sequentially.
Looking at the longer-term picture, BIO's 5-year compound annual growth rate (CAGR) stands at +0.3%, indicating moderate growth over time. The company achieved its highest annual revenue of $2.92 billion in 2021.
Revenue diversification analysis shows BIO's business is primarily driven by Clinical Diagnostics (60%), and Life Science (40%). With over half of revenue concentrated in Clinical Diagnostics, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including TMO (+5.4% YoY), DHR (+4.0% YoY), and BRKR (+2.1% YoY), BIO has underperformed the peer group in terms of revenue growth. Compare BIO vs TMO →
BIO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BIOCurrent | $2.6B | +1.1% | +0.3% | 10.5% | |
 TMO | $44.6B | +5.4% | +6.7% | 18.2% | |
 DHR | $24.6B | +4.0% | +2.0% | 20.9% | |
 BRKR | $3.4B | +2.1% | +10.2% | 7.5% | |
 RGEN | $738M | +17.4% | +15.0% | 8.1% | |
 CRL | $4.0B | -0.9% | +6.5% | 12.6% |
BIO Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.58B | +0.7% | $1.34B | 52.0% | $270.5M | 10.5% |
| 2024 | $2.57B | -3.9% | $1.38B | 53.7% | $269.0M | 10.5% |
| 2023 | $2.67B | -4.7% | $1.43B | 53.4% | $337.8M | 12.6% |
| 2022 | $2.80B | -4.1% | $1.57B | 55.9% | $482.6M | 17.2% |
| 2021 | $2.92B | +14.8% | $1.64B | 56.1% | $500.3M | 17.1% |
| 2020 | $2.55B | +10.1% | $1.44B | 56.5% | $421.3M | 16.6% |
| 2019 | $2.31B | +0.9% | $1.26B | 54.4% | $229.7M | 9.9% |
| 2018 | $2.29B | +6.0% | $1.22B | 53.5% | $-108,641,000 | -4.7% |
| 2017 | $2.16B | +4.4% | $1.19B | 55.0% | $116.7M | 5.4% |
| 2016 | $2.07B | +2.4% | $1.14B | 55.0% | $53.2M | 2.6% |
See BIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBIO — Frequently Asked Questions
Quick answers to the most common questions about buying BIO stock.
Is BIO's revenue growth accelerating or slowing?
BIO revenue growth slowed to +1.1%, below the 5-year CAGR of +0.3%. TTM revenue is $2.6B. The deceleration marks a shift from historical growth rates.
What is BIO's long-term revenue growth rate?
Bio-Rad Laboratories, Inc.'s 5-year revenue CAGR of +0.3% reflects the variable expansion pattern. Current YoY growth of +1.1% is near this long-term average.
How is BIO's revenue distributed by segment?
BIO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.